Chapter

Multiple Sclerosis and Related Disorders

Michael V. Johnston

in Principles of Drug Therapy in Neurology

Second edition

Published on behalf of Oxford University Press

Published in print September 2010 | ISBN: 9780195146837
Published online April 2013 | e-ISBN: 9780199322961 | DOI: http://dx.doi.org/10.1093/med/9780195146837.003.0436

Series: Contemporary Neurology Series

Multiple Sclerosis and Related Disorders

Show Summary Details

Preview

Treatment of multiple sclerosis (MS) has changed considerably with the advent of disease modifying therapies (DMTs) including the β-interferons, glatiramer (which is a mixture of synthetic polypeptides), and the monoclonal antibody natalizumabA2 Magnetic resonance imaging (MRI) has also led to earlier and more accurate diagnosis and staging of MS, and this information has become part of current diagnostic criteria.3–5 Evidence that MS permanently damages axons as well as white matter and that the disease has often been present for months or years prior to the first episode makes accurate diagnosis and early continuous therapy important for preventing disability.6–8 Long-term studies suggest that continued therapy is important to prevent relapses and progression of disease, but side effects and discomfort from repeated injections may limit compliance.2

Chapter.  5715 words.  Illustrated.

Subjects: Neurology

Full text: subscription required

How to subscribe Recommend to my Librarian

Buy this work at Oxford University Press »

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.